The Cost-Effectiveness of Efgartigimod Alfa (Vyvgart) in the Treatment of Myasthenia Gravis: An Insight

By Staff Writer

December 18, 2023

 The Purpose and Pricing of Efgartigimod Alfa

Efgartigimod Alfa, a drug designed to ameliorate symptoms of Generalised Myasthenia Gravis (gMG), has been reimbursed since April 2023 in Japan. The drug is priced at JPY 421,455 for Vyvgart® for intravenous infusion 400 mg as of September 2023. Center for Outcomes Research and Economic Evaluation for Health (C2H) calculate the price using a model for the Efgartigimod Alfa Cost-effectiveness. They then add a 5% usefulness premium and a 10% market premium. 

The Scope of the Efgartigimod Alfa Cost-effectiveness

The cost-effectiveness evaluation of Efgartigimod alfa targets two populations: acetylcholine receptor antibody-positive and antibody-negative patients. The comparators were prednisolone ± immunosuppressive drug ± acetylcholinesterase inhibitor.

Evaluation of Additional Benefits

The manufacturer did not conduct a systematic review in the base case analysis but evaluated the additional benefits of Efgartigimod alfa for patients with gMG as a whole. The academic group decided to evaluate based on scope. They assessed additional benefits for each population using the ADAPT trial. 

Results of the Cost-effectiveness Analysis

The manufacturer conducted a cost-utility analysis using a Markov model, which had states of Efgartigimod alfa or the comparator as first-line treatments, intravenous immunoglobulin or plasma exchange as second-line treatments, eculizumab as third-line treatment (only for population [a]), and the best supportive care.

The Expert Committee of Cost-Effectiveness Evaluation accepted the following:

Reference url

Recent Posts

Africa health partnership
      

Strengthening Africa Health Partnership

🌍 Can collaboration redefine Africa’s health landscape?

A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.

Look into the details of this transformative partnership and its implications for the future of healthcare in the region!

#SyenzaNews #globalhealth #HealthcareInnovation

breast cancer Africa
    

Urgent Call for Enhanced Breast Cancer Africa Control Measures

🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?

A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.

Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.

#SyenzaNews #globalhealth #oncology #HealthTech

Journavx pain management
   

Journavx Pain Management: FDA Approves New Non-Opioid Treatment for Acute Pain

💡 *Learn more about the new breakthrough in pain management*
The FDA has recently approved Journavx, the first of its kind in a new class of pain management drugs, offering a promising alternative to opioids for adults with moderate to severe acute pain. This innovative treatment targets pain-signaling pathways, providing a safer approach to relief.

Curious to learn more? Dive into the details of this significant advancement in healthcare!

#SyenzaNews #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.